The latest data point for RXRX's EPS in Q4'25 shows a loss of -0.17 USD, marking a notable improvement from the previous quarter's -0.36 USD in Q3'25 and representing the smallest quarterly loss in the observed period. Over the timeframe from Q1'23 to Q4'25, EPS has exhibited a fluctuating but generally declining trend, starting at -0.34 USD and reaching a low of -0.57 USD in Q4'24, before a partial recovery in 2025 with values improving from -0.50 USD in Q1'25 to -0.17 USD in Q4'25. Year-over-year EPS growth has been mostly negative, with declines as steep as -40% in Q4'23, though it turned positive in Q3'24 (+21%) and dramatically in Q4'25 (+70%), indicating accelerating profitability momentum despite ongoing losses. This bar and line chart highlights volatility typical of growth-stage companies, with no sustained positive EPS yet achieved.